Company Presentation & Networking
Join California Life Sciences and Daiichi Sankyo for an afternoon program and networking reception.
Daiichi Sankyo leadership will share an overview of the company’s global open innovation strategy and the work underway at its Research Institute San Diego, a growing hub for West Coast partnerships. Following these presentations, CLS’s head of Innovation & Entrepreneurship, Shikha Sharma, PhD, will moderate a discussion with startup CEOs who have built research collaborations with the Institute, covering what actually happens between a first conversation and a signed partnership.
Agenda
Date
October 21, 2026
time
3:00 PM – 7:00 PM
location
Timber + Tide
South San Francisco, CA
Format
Daiichi Sankyo company presentation and panel discussion, followed by a networking reception.
Time
program
description
3:00 – 3:15 PM
Registration & Check In
Check in and get settled before the program begins.
3:20 – 4:00 PM
Company Presentation
Company Introduction | Shiv Krishnan, PhD, Vice President, Global Business Development, Daiichi Sankyo
Global Open Innovation Activities | Wataru Tomisato, PhD, Head of Open Innovation Group, Daiichi Sankyo
RISD Introduction & Activities | Taka Nagayama, PhD, Head of Research Institute San Diego, Daiichi Sankyo
4:00 – 4:20 PM
Audience Q&A
Shikha Sharma, PhD, Sr. Director, Innovation & Entrepreneurship, California Life Sciences (Facilitator)
4:20 – 4:55 PM
Panel Discussion
‘Inside a Startup-Pharma Collaboration: From First Conversation to Partnership’
A candid conversation with startup CEOs who have firsthand experience building collaborations with Daiichi Sankyo Research Institute San Diego.
Panelists to be Announced
4:55 – 5:00 PM
Closing Remarks
Taka Nagayama, PhD, Head of Research Institute San Diego, Daiichi Sankyo
5:00 – 7:00 PM
Networking Reception
Connect with Daiichi Sankyo leadership, fellow attendees, and continue the conversation over hosted refreshments and small bites.
This event is closed to service providers, consultants, recruiters, and healthcare professionals.
Registrations that don’t match a ticket category may be cancelled.
About Daiichi Sankyo
Daiichi Sankyo is a global healthcare company headquartered in Japan, committed to becoming a trusted healthcare innovator, transforming the lives of people through its strength in science and technology. The company discovers and develops new standards of care to address diverse medical needs to fulfill its purpose of contributing to the enrichment of quality of life around the world.
With a strategic focus on oncology, Daiichi Sankyo is advancing an industry-leading antibody drug conjugate portfolio along with identifying new breakthrough generating technologies to deliver practice-changing medicines to patients, healthcare professionals and society.
The Daiichi Sankyo Research Institute San Diego serves as a key hub for external innovation and partnership across the West Coast region.
global headquarters
Tokyo, Japan — with an expanding research presence in San Diego, CA
scientific heritage
125+ years of drug discovery and development
partnership goals
Asset licensing, external research agreements, and regionally focused collaborations
Recent Daiichi Sankyo Research Institute San Diego Collaborations
Daiichi Sankyo has entered into a research collaboration with SylamoreBio that focuses on central nervous system applications, utilizing the SyLEC module—a specialized delivery platform engineered to transport therapeutic cargo across complex biological barriers to achieve high-efficiency cellular uptake and broad tissue penetration.
Daiichi Sankyo has entered into a research collaboration with Qymune on a multi-phase to evaluate its next-generation T-cell engager platform for a novel oncology program to advance new approaches to targeted cancer therapies.
Daiichi Sankyo has entered into a research collaboration with Voro Therapeutics to evaluate its PrimeBody platform for tumor-activated antibody drug conjugates to advance more precise and targeted approaches to cancer treatment.
